NICE limits coverage of J&J, Takeda myeloma combo by Angus Liu Tuesday, March 12, 2019 J&J's Darzalex is on track to nab a second first-line myeloma nod in the U.S., but its reimbursement journey in England hasn't been so smooth.
How can J&J cope with careening Xarelto sales? by Carly Helfand Tuesday, January 22, 2019 Competition and discounting are unsurprisingly taking a toll on J&J’s older drugs. But cardiovascular product Xarelto is also on that list.
J&J's fast-growing Darzalex lines up for 2nd 1L myeloma nod by Carly Helfand Tuesday, December 4, 2018 J&J's Darzalex made multiple myeloma history in May with an FDA nod in newly diagnosed patients. And now, it’s looking for a repeat.
Takeda maintenance data set up Ninlaro for new nod by Carly Helfand Sunday, December 2, 2018 Three years after its initial approval, Takeda’s Ninlaro may finally be ready to jump into a new indication.
J&J's Darzalex ambitions take a hit with scrapped I-O trials by Carly Helfand Tuesday, May 29, 2018 Drugmakers have hoped that pairing their cancer drugs with I-O treatments would improve benefits. Not for Genmab and J&J.
J&J's Darzalex snags landmark myeloma approval by Carly Helfand Tuesday, May 8, 2018 Johnson & Johnson’s Darzalex just vaulted ahead of its myeloma competitors—and it has plenty of them.
J&J's Darzalex wins limited NICE approval for multiple myeloma by Eric Palmer Wednesday, January 17, 2018 While Johnson & Johnson’s multiple myeloma drug Darzalex has steadily won new approvals from the FDA, it continues to face obstacles in England.
J&J's Darzalex wins big in first-line myeloma by Carly Helfand Tuesday, December 12, 2017 J&J has succeeded in moving Darzalex earlier into multiple myeloma therapy, and it now has data that could help it win a first-line nod.
